Skip to main
CAPR

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc has demonstrated a substantial increase in the projected enterprise value of its lead product, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy, raising it from $794 million to $2.30 billion, reflecting positive Phase III clinical trial results. The promising data indicates a significant 1.0 point improvement in the PUL 2.0 Mid-level Dimension, along with improvements in heart scarring among patients, underscoring the therapeutic potential of deramiocel. Furthermore, the anticipated revenue from the partnership with NSPharma enhances the financial outlook, suggesting a robust opportunity for significant net sales and overall growth in shareholder value.

Bears say

Capricor Therapeutics Inc faces significant clinical risks associated with its lead product, deramiocel, including potential challenges in safety, tolerability, and efficacy, which could hinder its progress through clinical trials and market approval. Additionally, the company may experience a slower-than-anticipated market penetration and revenue ramp, increasing the likelihood of needing to secure additional financing under unfavorable conditions, leading to potential shareholder dilution. Compounding these risks, recent data indicates a concerning decline in left ventricular ejection fraction (LVEF) among Duchenne muscular dystrophy patients, suggesting that the therapeutic market potential for deramiocel may not meet initial projections.

Capricor Therapeutics (CAPR) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.